Drug intelligence / Profile preview

Caterpil

Development stage
Unknown
Lead developer
Bion Therapeutics
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Topical
01

Overview

Caterpil is a topical pain-relieving gel developed by Bion Therapeutics. It is formulated with a combination of active ingredients, including diclofenac (1.5%), linseed oil, methyl salicylate, menthol, camphor, and capsaicin. The gel is designed for the localized management of musculoskeletal pain, inflammation, sprains, strains, and joint discomfort associated with conditions such as arthritis and ankylosing spondylitis. Diclofenac acts as a non-steroidal anti-inflammatory drug (NSAID) by inhibiting cyclooxygenase enzymes (COX-1 and COX-2) to reduce prostaglandin synthesis. Methyl salicylate, menthol, and camphor function as counter-irritants that stimulate sensory receptors (such as TRPM8 and TRPV3) to produce cooling and warming sensations, thereby distracting from deeper pain. Capsaicin desensitizes local nociceptors by activating and subsequently defunctionalizing TRPV1 channels, while linseed oil acts as an anti-inflammatory agent and penetration enhancer to facilitate deep tissue absorption.

Brand names
CaterpilCaterpil Gel
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV3 (Transient receptor potential vanilloid subtype 3)

Beyond the preview

Go deeper on Caterpil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caterpil.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call